Nomura Financial Advisory & Securities (India) Pvt.Ltd.
IPOs where Nomura Financial Advisory & Securities (India) Pvt.Ltd. acted as a book-running lead manager, with each issue’s size and listing outcome.
Track record on ipostation
ipostation's database lists Nomura Financial Advisory & Securities (India) Pvt.Ltd. as a book-running lead manager on 4 IPOs: all of them mainboard issues. Bidding dates recorded here run from Aug 2026 to Aug 2026, and 2 issues have no bidding date recorded yet. Of these, 2 have listed and 2 are at the draft-filing (announced) stage. It shared every one of these mandates with at least one other lead manager.
Issue size is recorded for 3 of the 4 IPOs. They range from ₹1,757 Cr (Symbiotec Pharmalab) to ₹3,066.89 Cr (Dhoot Transmission), with a median of ₹1,800 Cr. The 2 listed issues with a recorded size total ₹4,823.89 Cr; sizes for issues that have not listed are the amounts stated in their offer documents.
A listing-day change is recorded for 2 listed issues: 1 above and 1 below the issue price. The median change was +18.0%, from -1.0% (Symbiotec Pharmalab) to +37.1% (Dhoot Transmission). These are past listing outcomes and say nothing about how a future issue will list.
Final overall subscription is recorded for both issues whose bidding has closed. The median was 75.07x, ranging from 75.06x (Dhoot Transmission) to 75.08x (Symbiotec Pharmalab).
Nomura Financial Advisory & Securities (India) Pvt.Ltd. has worked alongside 13 other lead managers on these issues. The 5 most frequent, by number of shared issues:
- Jefferies India Pvt.Ltd. — 2 shared issues
- JM Financial Ltd. — 2 shared issues
- Kotak Mahindra Capital Co.Ltd. — 2 shared issues
- 360 One WAM Ltd. — 1 shared issue
- Avendus Capital Pvt.Ltd. — 1 shared issue
IPOs with Nomura Financial Advisory & Securities (India) Pvt.Ltd. as lead manager
| IPO | Board | Status | Open date | Issue size | Price | Subscription | Listing gain |
|---|---|---|---|---|---|---|---|
| AGS Health | Mainboard | Announced | — | ₹1,800 Cr | — | — | — |
| InCred | Mainboard | Announced | — | — | — | — | — |
| Symbiotec Pharmalab | Mainboard | Listed | 24 Aug 2026 | ₹1,757 Cr | ₹988 | 75.08x | -1.0% |
| Dhoot Transmission | Mainboard | Listed | 10 Aug 2026 | ₹3,066.89 Cr | ₹871 | 75.06x | +37.1% |
Subscription is the final overall figure once bidding has closed; listing gain is the listing-day change against the issue price. “—” means not available.
Year by year
| Bidding year | IPOs | Mainboard | SME | Total issue size | Median listing gain |
|---|---|---|---|---|---|
| 2026 | 2 | 2 | 0 | ₹4,823.89 Cr | +18.0% (2 listed) |
| Not yet scheduled | 2 | 2 | 0 | ₹1,800 Cr | — |
What a book-running lead manager does
Under Regulation 23 of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, an issuer must appoint one or more SEBI-registered merchant bankers, at least one of whom is a lead manager to the issue. When more than one merchant banker manages an issue, each one’s responsibilities for disclosures, allotment, refunds and underwriting are fixed in advance and set out in the draft offer document and the offer document.